Hem/Onc Roundup: Experts Discuss BCMA CAR T for Relapsed/Refractory MM, and More

This week on DocWire, editors spoke with Dr. Saad Usmani about the latest efficacy and safety data for cilta-cel, the BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma. The FDA recently granted priority review of cilta-cel’s biologic license application.

https://www.docwirenews.com/condition-center/multiple-myeloma-knowledge-hub/dr-saad-usmani-discusses-effective-treatment-for-relapsed-refractory-multiple-myeloma/

–

How Does Chemotherapy Impact Gut Health?

In other news, myelosuppressive chemotherapy was found to be associated with changes and disruptions to patient gut health in patients with solid tumors. The investigators noted an increase in the presence of Proteobacteria, which has previously been linked to increased infection risk in patients with cancer.

https://www.docwirenews.com/docwire-pick/how-does-chemotherapy-impact-gut-health/

–

Melanoma, Lung Cancer Death Has Declined in the U.S.

A new report found an overall decrease in mortality due to cancer across men and women and all racial/ethnic groups between 2001 and 2018. Due due to skin and lung cancer have decreased overall, but improvements in mortality for breast and prostate cancer appeared to have stalled.

https://www.docwirenews.com/docwire-pick/melanoma-lung-cancer-death-has-declined-in-the-u-s/

–

Home Test for Colon Cancer Can Lead to Unexpected Medical Bill

Consumers are finding that follow-up colonoscopy after a positive result from a popular at-home colon cancer screening test may not be covered by insurance. A Missouri woman reported $1,900 in medical expenses after using the popular at-home colon cancer screening test Cologuard.

https://www.docwirenews.com/hematology-oncology/home-test-for-colon-cancer-can-lead-to-unexpected-medical-bill/